Vir Biotechnology, Inc.
Nasdaq VIR · San Francisco, CA
Works in GI & liver · Infectious disease · Renal & urogenital · Respiratory · Women's health
Vir Biotechnology, Inc. is a clinical trial sponsor based in San Francisco, CA, listed as Nasdaq VIR. It has 6 active clinical trials with 1,564 planned participants, across 5 therapeutic areas. Since 2021 it has completed 12 trials and stopped 3 early.
Trial track record · since 2021
Financials · Nasdaq VIR
Fundraising
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Vir Biotechnology, Inc
Vir Biotechnology, Inc is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 1,564 planned participants, in GI & liver, Infectious disease, Renal & urogenital, Respiratory and other areas. Since 2021 it has completed 12 trials and stopped 3 early.
Vir Biotechnology, Inc is based in San Francisco, CA and is listed as Nasdaq VIR. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Vir Biotechnology, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Vir Biotechnology, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.